Novo to Cut Over a Fifth of Jobs at Ex-Catalent Plant in Indiana

Novo Nordisk A/S plans to cut more than a fifth of the jobs at an Indiana factory that has fallen short on US quality standards since it was acquired by the Danish drugmaker in its $11 billion purchase of Catalent Inc.

About 400 of the 1,800 positions at the Bloomington site will be cut, a Novo spokeswoman said by email. Workers will be notified in early May.

The US Food and Drug Administration warned late last year Novo hadn’t done enough to tackle violations of good manufacturing practices at the site — including contamination from mammal hair. The site ...